---
title: "I-Mab Reports H1 2025 Financial Results Amid Strategic Shift"
description: "I-Mab (IMAB) reported its H1 2025 financial results on October 6, 2025, amid a strategic shift involving the divestiture of Greater China assets and internal restructuring to cut R&D expenses. This ch"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260044858.md"
published_at: "2025-10-06T11:28:52.000Z"
---

# I-Mab Reports H1 2025 Financial Results Amid Strategic Shift

> I-Mab (IMAB) reported its H1 2025 financial results on October 6, 2025, amid a strategic shift involving the divestiture of Greater China assets and internal restructuring to cut R&D expenses. This change may affect operations and market positioning. Analysts rate IMAB stock as a Buy with a $9.00 target, but Spark's AI Analyst gives it a Neutral score due to financial challenges, ongoing losses, and a negative P/E ratio. I-Mab focuses on developing biologics for unmet medical needs in immuno-oncology and autoimmune diseases.

The latest update is out from I-MAB ( (IMAB) ).

On October 6, 2025, I-Mab announced its financial results for the first half of 2025, highlighting unaudited condensed consolidated financial statements. The announcement is part of a strategic reprioritization, including the divestiture of its Greater China assets and internal restructuring, which is expected to reduce research and development expenses. This move is likely to impact the company’s operations and market positioning, potentially affecting stakeholders and future financial performance.

The most recent analyst rating on (IMAB) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.

**Spark’s Take on IMAB Stock**

According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.

The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.

To see Spark’s full report on IMAB stock, click here.

**More about I-MAB**

I-Mab is a biopharmaceutical company focused on the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly in the areas of immuno-oncology and autoimmune diseases.

**Average Trading Volume:** 2,220,915

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $342.1M

For an in-depth examination of IMAB stock, go to TipRanks’ Overview page.

### Related Stocks

- [IMAB.US - I-Mab](https://longbridge.com/en/quote/IMAB.US.md)
- [NBP.US - NovaBridge Biosciences](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| I-Mab Announces Strategic Transformation and Rebranding to NovaBridge Biosciences | I-Mab has announced a strategic transformation to become NovaBridge Biosciences, pending shareholder approval. The compa | [Link](https://longbridge.com/en/news/261504233.md) |
| I-MAB Releases Promising Phase I Data for Givastomig in Advanced Gastric Cancer | I-MAB has announced promising Phase I data for Givastomig, a bispecific antibody targeting Claudin 18.2, in advanced gas | [Link](https://longbridge.com/en/news/262671237.md) |
| 16:00 ETBarzolvolimab Provides Long-Term Improvements for Spontaneous Urticaria | Barzolvolimab has shown long-term efficacy in treating spontaneous urticaria, with significant improvements observed in  | [Link](https://longbridge.com/en/news/275655959.md) |
| UW-Madison requiring students to disclose measles vaccination status | The University of Wisconsin-Madison has mandated that students disclose their vaccination status for diseases including  | [Link](https://longbridge.com/en/news/275930065.md) |
| MAP: Which states have the most measles cases in 2026? | In 2026, the U.S. faces over 900 confirmed measles cases across nearly half the states, with five new outbreaks reported | [Link](https://longbridge.com/en/news/276010501.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
